Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a BetZacks Investment Research • 01/27/26
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MGlobeNewsWire • 01/23/26
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockGlobeNewsWire • 01/22/26
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved UponSeeking Alpha • 01/21/26
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should KnowSeeking Alpha • 01/21/26
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug DataThe Motley Fool • 01/20/26
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 TranscriptSeeking Alpha • 01/20/26
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/20/26
Why Small Biotech Stock Corvus Pharma Just Launched To An Eight-Year HighInvestors Business Daily • 01/20/26
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 01/16/26
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/04/25
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewsWire • 10/31/25
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025GlobeNewsWire • 10/28/25
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025GlobeNewsWire • 10/17/25
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 CatalystsSeeking Alpha • 08/13/25
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/07/25
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 06/04/25
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/25